Abiopharma

Merck and Eisai Announce WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma

GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights

Regeneron Reports Third Quarter 2025 Financial and Operating Results

Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025

Zymeworks Announces Participation in Upcoming Investor Conferences

Rockwell Medical to Exhibit at ASN Kidney Week 2025

LNTH Investors Have Opportunity to Lead Lantheus Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Qualigen Therapeutics to Rebrand as AIxCrypto After Stockholder Meeting on November 12, with Three Core Goals for 2025

Change of Directors Interest Notice

Notification regarding unquoted securities - MSB